105 cells of the exponentially expanding murine Ink4a/Arf(−/−) EGFRvIII or G12 cells were injected into 4-5weeks old athymic nude mice using a mouse stereotaxic instrument (Stoelting Co, Wood Dale, IL) according to the protocol previously described [45 (link)]. Survival was recorded until the onset of neurologic sequelae or cachexia. Mice were euthanized in accordance with our institutional guidelines for animal welfare and experimental conduct. The survival curve was calculated by GraphPad Prism 5 (GraphPad, La Jolla, CA) using the method of Kaplan-Meier. p values were analyzed using the logrank (Mantel-Cox) test.
TMZ was given at 15 mg/kg by oral gavage once per day for three days at indicated time point after implantation. BI2536 was given consecutively at 25 mg/kg by i.v. injection twice per week for four weeks beginning at indicated time point. Gefitinib was administered via oral gavage at 200 mg/kg weight once per day, 5 days per week for four weeks. For all experiments, 5-6 mice were randomized to each treatment group.
TMZ was given at 15 mg/kg by oral gavage once per day for three days at indicated time point after implantation. BI2536 was given consecutively at 25 mg/kg by i.v. injection twice per week for four weeks beginning at indicated time point. Gefitinib was administered via oral gavage at 200 mg/kg weight once per day, 5 days per week for four weeks. For all experiments, 5-6 mice were randomized to each treatment group.
Free full text: Click here
